SCHEDULE: Saba Capital Amends abrdn Life Sciences Stake to 7.88%

Saba Capital Management, L.P. and its affiliates have amended their beneficial ownership in abrdn Life Sciences Investors to 7.88% of common shares, reporting recent open market transactions.

Summary

• Saba Capital Management, L.P., Saba Capital Management GP, LLC, and Boaz R. Weinstein (collectively, the "Reporting Persons") beneficially own 2,274,356 common shares of abrdn Life Sciences Investors.
• This ownership represents 7.88% of the issuer's common stock, calculated based on 28,872,416 shares outstanding as of March 31, 2025, as disclosed in the company's N-CSRS filed on June 9, 2025.
• The total approximate amount paid to acquire the reported common shares is $29,826,505.
• Funds for the purchases were derived from investor subscription proceeds, capital appreciation, and margin account borrowings.
• The filing is an Amendment No. 9 to a previous Schedule 13D, updating beneficial ownership and transaction details.
• The Reporting Persons explicitly state that the purpose of the transaction is "Not Applicable," indicating no stated intent to change or influence control of the issuer.

Sentiment

Score: 5

Explanation: The filing is neutral in sentiment regarding the issuer's performance, as it primarily reports an amendment to beneficial ownership and trading activity by an institutional investor. The net selling activity by Saba Capital could be viewed with slight caution, but without stated intent, it is difficult to assign a strong negative sentiment.

Positives

• Saba Capital, a prominent institutional investor, maintains a significant 7.88% stake in abrdn Life Sciences Investors, indicating continued investment interest.

Negatives

• Saba Capital engaged in net selling of 370,296 shares (118,540 shares bought vs. 488,836 shares sold) between September 26, 2025, and November 21, 2025, which could be interpreted as a reduction in conviction or a portfolio rebalancing.

Risks

• The filing does not explicitly detail specific risks pertaining to abrdn Life Sciences Investors.
• Reporting Persons have not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
• Reporting Persons have not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws, or finding any violation with respect to such laws, during the last five years.

Future Outlook

The filing does not contain any forward-looking statements or guidance from the issuer or the reporting persons regarding the issuer's future performance or strategic direction.

Industry Context

This filing primarily concerns a change in beneficial ownership by an institutional investor and does not provide specific details on broader industry trends or competitive analysis for abrdn Life Sciences Investors.

Legal Proceedings

• Reporting Persons have not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
• Reporting Persons have not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws, or finding any violation with respect to such laws, during the last five years.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake and recent net selling activity provides transparency, which may influence other investors' perceptions and trading decisions.

Key Dates

Recommendation

While Saba Capital maintains a substantial 7.88% stake, the recent net selling activity suggests a potential rebalancing or reduced conviction by a key institutional investor. Without further information on Saba Capital's intent or the issuer's operational performance, a 'hold' recommendation is prudent, advising investors to monitor future filings and company developments.

Keywords

abrdn Life Sciences Investors, Saba Capital Management, Boaz R. Weinstein, Schedule 13D/A, beneficial ownership, institutional investment, common shares, equity stake, life sciences investment